回顾性见解:来自中国的403例ILC病例的临床特征和存活率

Javaria Nasir1,2, Boyue Han1,2,3, Xin Hu1,2,3

  • 1Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China.

BMC cancer
|July 18, 2025
PubMed
概括

侵袭性叶囊癌 (ILC) 患者比侵袭性管道癌 (IDC) 患者面临更差的生存率和更高的转移风险. 进一步的研究对于开发有针对性的ILC治疗至关重要.